Hi and welcome,
I'd not heard of this before but i found some information for you , it looks like it is still in early research stages for MS....
LA has been studied as an effective therapy in a rat model of multiple sclerosis and experimental autoimmune encephalomyelitis. ALA dose dependently prevented the development of clinical signs in this model. LA has a protective effect on encephalomyelitis development not only by affecting the migratory capacity of monocytes, but also by stabilizing the blood-brain barrier. 10
Mouse studies have shown that LA suppresses the migration of T cells across the blood-brain barrier in the spinal cord. Additionally, LA inhibited expression of intracellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) by CNS endothelial cells in experimental autoimmune encephalomyelitis. LA was also effective in preventing experimental autoimmune encephalomyelitis development in a dose-dependent fashion. It was shown that reactive oxygen species are important mediators of injury in experimental autoimmune encephalomyelitis and that generation of reactive oxygen species can be decreased by LA. LA also decreased the migration of monocytes across the blood-brain barrier, which correlated with clinical improvement seen in experimental autoimmune encephalomyelitis. In other studies, LA decreased the phagocytosis of myelin by macrophages by inhibiting the generation of reactive oxygen species. 5
A placebo-controlled phase 1 clinical trail of 37 subjects studied the effects of oral racemic LA in multiple sclerosis. Subjects were randomly assigned to 4 groups, including placebo. The other 3 groups received LA 600 mg twice a day, 1,200 mg once a day, or 1,200 mg twice a day, for 14 days. The study found LA to be generally well tolerated, but peak plasma levels of LA varied among subjects. As would be expected in a short duration study, there was no change in disability caused by multiple sclerosis as assessed by the Expanded Disability Status Score. The study found that stable blood levels of LA required a dose of 1,200 mg, and treatment was associated with changes in serum immunologic markers associated with T-cell migration into the CNS. Longer-duration trials with a larger number of multiple sclerosis subjects are needed to establish the ability of LA to decrease disease activity. 5
Hope that helps.....JJ